VEGFA and neoplasm: This lack of therapeutic efficacy may be due to compensation by other angiogenic factors thereby resulting in resistance to anti-VEGF therapy (3, 13, 14), or simply due to a lack of sprouting angiogenesis in lymph nodes during early tumor dissemination (15, 16).